Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase c-δ and glycogen synthase kinase 3β

Anesthesiology

Volumn 111, Issue 5, 2009, Pages 1036-1043

  Inamura, Yoshitaka ^a   Miyamae, Masami ^b   Sugioka, Shingo ^a   Kaneda, Kazuhiro ^a   Okusa, Chika ^a   Onishi, Anna ^a   Domae, Naochika ^b   Kotani, Junichiro ^a   Figueredo, Vincent M ^c  

^a Department of Anesthesiology ^*

^b OSAKA DENTAL UNIVERSITY   (Japan)

^c ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; GLYCOGEN SYNTHASE KINASE 3BETA; NITRIC OXIDE; PENTOBARBITAL; PROTEIN KINASE B; PROTEIN KINASE C DELTA; SEVOFLURANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONDITIONING; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GUINEA PIG; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; SENSOR; WESTERN BLOTTING;

EID: 70350450413     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181bbbf9b     Document Type: Article

References (47)

1. Bull DA, Maurer J: Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 2003; 75:S735-9
2. Khan TA, Bianchi C, Voisine P, Feng J, BakerJ, Hart M, Takahashi M, Stahl G, Sellke FW: Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg 2004; 128: 602-608
3. Carter J, Buerke U, Rossner E, Russ M, Schubert S, Schmidt H, Ebelt H, Pruefer D, Schlitt A, Werdan K, Buerke M: Anti-inflammatory actions of aprotinin provide dose-dependent cardioprotection from reperfusion injury. Br J Pharmacol 2008; 155:93-102
4. Mouton R, Finch D, Davies I, Binks A, Zacharowski K: Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: A retrospective observational study. Lancet 2008; 371:475-482
5. Hausenloy DJ, Pagano D, Keogh B: Aprotinin: Still courting controversy. Lancet 2008; 371:449-450
6. Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-365
7. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J: Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297:471-479
8. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM: A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46:327-338
9. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, MathewJP, Peterson ED, Newman MF: The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358:784-793
10. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC: Isoflurane mimics ischemic preconditioning via activation of KATP channels: Reduction of myocardial infarct size with an acute memory phase. ANESTHESIOLOGY 1997; 87: 361-370
11. Preckel B, Schlack W, Comfere T, Obal D, Barthel H, Thamer V: Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth 1998; 81:905-912 (Pubitemid 28561325)
12. Zaugg M, Lucchinetti E, UeckerM, Pasch T, Schaub MC: Anaesthetics and cardiac preconditioning, I: Signalling and cytoprotective mechanisms. Br J Anaesth 2003; 91:551-565 (Pubitemid 37264906)
13. Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Domae N, Kotani J, Figueredo VM: Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts. Anesth Analg 2008; 106:9-16
14. Pagel PS: Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J Cardiothorac Vasc Anesth 2008; 22:753-765
15. Amour J, Brzezinska AK, Weihrauch D, Billstrom A, ZielonkaJ, Krolikowski JG, BienengraeberMW, Warltier DC, Philip FJ, Kersten JR: Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. ANESTHESIOLOGY 2009; 110:317-325
16. Novalija E, Fujita S, Kampine JP, Stowe DF: Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts. ANESTHESIOLOGY 1999; 91:701-712
17. Riess ML, Kevin LG, McCormick J, Jiang MT, Rhodes SS, Stowe DF: Anesthetic preconditioning: The role of free radicals in sevoflurane-induced attenuation of mitochondrial electron transport in Guinea pig isolated hearts. Anesth Analg 2005; 100:46-53
18. Uecker M, Da Silva R, Grampp T, Pasch T, Schaub MC, Zaugg M: Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning. ANESTHESIOLOGY 2003; 99:138-147
19. Okusa C, Miyamae M, Sugioka S, Kaneda K, Inamura Y, Onishi A, Domae N, Kotani J, Figueredo VM: Acute memory phase of sevoflurane preconditioning is associated with sustained translocation of PKC-a and s, but not 8 in isolated guinea pig hearts. Eur J Anaesthesiol 2009; 26:582-588
20. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M: Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3/3. ANESTHESIOLOGY 2005; 103:987-995
21. Ulker S, McKeown PP, Bayraktutan U: Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc Res 2002; 55:830-837
22. Samama CM, Mazoyer E, Bruneval P, Ciostek P, Bonnin P, Bonneau M, Roussi J, Bailliart O, Pignaud G, Viars P, Caen JP, Drouet LO: Aprotinin could promote arterial thrombosis in pigs: A prospective randomized, blind study. Thromb Haemost 1994; 71:663-669
23. Cosgrove DM III, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, McCarthy PM, Loop FD: Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-1036
24. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W: Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981; 101:593-600
25. Mochizuki S, Himi N, Miyasaka T, Nakamoto H, Takemoto M, Hirano K, Tsujioka K, Ogasawara Y, Kajiya F: Evaluation of basic performance and applicability of a newly developed in vivo nitric oxide sensor. Physiol Meas 2002; 23:261-268
26. Feng J, Fischer G, Lucchinetti E, Zhu M, Bestmann L, Jegger D, Arras M, Pasch T, Perriard JC, Schaub MC, Zaugg M: Infarct-remodeled myocardium is receptive to protection by isoflurane postconditioning: Role of protein kinase B/Akt signaling. ANESTHESIOLOGY 2006; 104:1004-1014
27. Tessier-Vetzel D, Tissier R, Waintraub X, Ghaleh B, Berdeaux A: Isoflurane inhaled at the onset of reperfusion potentiates the cardioprotective effect of ischemic postconditioning through a NO-dependent mechanism. J Cardiovasc Pharmacol 2006; 47:487-492
28. Obal D, Scharbatke H, Barthel H, Preckel B, Mullenheim J, Schlack W: Cardioprotection against reperfusion injury is maximal with only two minutes of sevoflurane administration in rats. Can J Anaesth 2003; 50:940-945
29. Bukhari EA, Krukenkamp IB, Burns PG, Gaudette GR, SchulmanJJ, al-Fagih MR, Levitsky S: Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? Ann Thorac Surg 1995; 60:307-310
30. Tsutsumi YM, Yokoyama T, Horikawa Y, Roth DM, Patel HH: Reactive oxygen species trigger ischemic and pharmacological postconditioning: in vivo and in vitro characterization. Life Sci 2007; 81:1223-1227
31. Weiss JN, Korge P, Honda HM, Ping P: Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003; 93:292-301
32. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M: Postconditioning inhibits mitochondrial permeability transition. Circulation 2005; 111:194-197 (Pubitemid 40139731)
33. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC: Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic-induced postconditioning in rabbits. ANESTHESIOLOGY 2005; 102:102-109
34. Krolikowski JG, Bienengraeber M, Weihrauch D, Warltier DC, Kersten JR, Pagel PS: Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesth Analg 2005; 101:1590-1596
35. Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D, Losano G, Pagliaro P: Post-conditioning reduces infarct size in the isolated rat heart: Role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 2006; 101:168-179
36. Heusch G, Boengler K, Schulz R: Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118:1915-1919
37. Heusch G, Post H, Michel MC, Kelm M, Schulz R: Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res 2000; 87:146-152 (Pubitemid 30616911)
38. BrudaNL, Hurlbert BJ, Hill GE: Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin Sci (Lond) 1998; 94:505-509
39. Ulker S, CinarMG, Bayraktutan U, Evinc A: Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells. Cardiovasc Res 2001; 50:589-596
40. Yoshida K, Mizukami Y, Kitakaze M: Nitric oxide mediates protein kinase C isoform translocation in rat heart during postischemic reperfusion. Biochim Biophys Acta 1999; 1453:230-238
41. Costa AD, Garlid KD: Intramitochondrial signaling: Interactions among mitoKATP, PKC-e, ROS, and MPT. Am J Physiol Heart Circ Physiol 2008; 295: H874-82
42. Nathan C, Xie QW: Nitric oxide synthases: Roles, tolls, and controls. Cell 1994; 78:915-918
43. Hardy JF, Desroches J: Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth 1992; 39:353-365
44. Fritz H, Wunderer G: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforsch 1983; 33:479-494
45. Hoffmann H, Siebeck M, Thetter O, Jochum M, Fritz H: Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. Adv Exp Med Biol 1989; 247B:35-42
46. Halestrap AP, Clarke SJ, Javadov SA: Mitochondrial permeability transition pore opening during myocardial reperfusion: A target for cardioprotection. Cardiovasc Res 2004; 61:372-385
47. Obal D, Preckel B, Scharbatke H, Mullenheim J, Hoterkes F, Thamer V, Schlack W: One MAC of sevoflurane provides protection against reperfusion injury in the rat heart in vivo. Br J Anaesth 2001; 87:905-911